Johnson & Johnson 2002 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 29, 2002. Johnson & Johnson is a global healthcare company employing approximately 108,300 people across over 200 operating companies in virtually all countries. The company operates under a decentralized management structure with three primary segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics.
Key Financial Metrics
The filing text incorporates detailed financial statements by reference and does not provide a consolidated table of revenue, profit, or cash flow totals within the provided text. However, the following specific metrics are disclosed:
- Research & Development Costs: $3,957 million for fiscal year 2002 (compared to $3,591 million in 2001 and $3,105 million in 2000). These costs are charged directly to income.
- Key Product Revenue Contribution: PROCRIT/EPREX (epoetin alfa) accounted for 11.8% of total revenues in 2002.
- Major Distributor Concentration: Sales to the three largest distributors (AmerisourceBergen Corp., McKesson HBOC, and Cardinal Distribution) accounted for 10.3%, 9.8%, and 9.2% of total revenues, respectively.
- Market Capitalization: The aggregate market value of voting and non-voting common stock held by non-affiliates was approximately $156 billion as of the last business day of the second fiscal quarter.
- Shares Outstanding: 2,969,972,365 shares of Common Stock as of February 25, 2003.
- Valuation Reserves: Total reserves deducted from accounts receivable (doubtful accounts, customer rebates, cash discounts) totaled $527 million at the end of 2002.
Material Changes and Operational Highlights
While specific year-over-year revenue growth percentages are not explicitly stated in the provided text, the following operational changes and data points are noted:
- R&D Investment Increase: Research costs increased by approximately 10.2% from 2001 to 2002 ($3,591 million to $3,957 million).
- Seasonality: Sales do not reflect significant seasonality, though spending is heavier in the fourth quarter due to advertising and research grants.
- Legal Proceedings: The company is involved in various Superfund proceedings regarding environmental remediation costs, which management does not expect to have a material adverse effect on operations.
- Management Changes: John W. Snow resigned from the Board of Directors (reported in an 8-K filed January 30, 2003).
Guidance, Risks, and Contingencies
The filing text does not contain specific forward-looking financial guidance or numerical outlooks for future periods. However, it highlights the following risks and contingencies:
- Regulatory Environment: Increasing stringency in government regulation (FDA, European Economic Community) regarding product safety, efficacy, and pricing. Managed care is noted as a potent force affecting drug and device pricing and utilization.
- Competition: Strong competition in all product lines, particularly in research and development, leading to potential product obsolescence.
- International Risks: Investments outside the U.S. are subject to higher risks due to restrictive economic policies and political uncertainties.
- Patent Dependence: While the company holds many patents, no single patent is considered material to the whole business except for those related to PROCRIT/EPREX.
- Internal Controls: Management concluded that disclosure controls and procedures were effective as of the evaluation date, with no significant changes or material weaknesses identified.
Investor Verification Checklist
- Verify the full consolidated revenue, net income, and cash flow figures in the referenced Annual Report to Shareholders (pages 38-56), as these totals are not present in the 10-K text provided.
- Review the "Legal Proceedings" note (Note 18) in the Annual Report for details on the Superfund proceedings and other litigation.
- Confirm the impact of the 11.8% revenue concentration from PROCRIT/EPREX on the Pharmaceutical segment's stability.
- Assess the implications of the $3.957 billion R&D spend on future product pipelines and profitability.
- Monitor the regulatory landscape for changes in drug pricing and managed care policies that could affect margins.